Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasms 5Prostatic Neoplasms, Castration-Resistant 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

enzalutamide 4darolutamide 2xentuzumab 1olaparib 1ipatasertib 1ibrutinib 1gallium 68 PSMA-11 1atezolizumab 1apalutamide 1TVB-2640 1Rosuvastatin Calcium 1Pioglitazone 1JNJ-64619178 1JNJ-64264681 1Docetaxel 1(225)Ac-PSMA-617 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Prostatic Neoplasms, Castration-Resistant × xentuzumab × Clear all
NCT02204072 2025-07-15

BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC)

Boehringer Ingelheim

Phase 1 Completed
120 enrolled 28 charts
Genitourinary

Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡